Plasminogen and matrix metalloproteinase activation by enzymatically modified low density lipoproteins in monocytes and smooth muscle cells

Summary

Protease activity promotes the progression and rupture of atherosclerotic plaques. LDL has been described to become enzymatically modified within the vessel wall yielding an atherogenic moiety (E-LDL). We studied the effect of E-LDL on the activation of plasminogen and matrix metalloproteinases (MMPs) in mono-cytes and vascular smooth muscle cells (VSMCs) as well as on MMP activation during cellular interactions. Human monocytes, monocytic MonoMac6 cells and human VSMCs were incubated with human native LDL (n-LDL) or E-LDL for 24 hours. E-LDL in contrast to n-LDL induced substantial activation of the plasminogen activation system as well as of the MMP system in monocytic cells, as measured by enhanced cell surface expression of the urokinase receptor (uPAR), the extracellular matrix metalloproteinase Inducer (EMMPRIN) and the membrane type-1 MMPs (MT1-MMP, MMP-14), as well as by secretion of active uPA, and of MMP-9. Consistently, E-LDL-treated monocytes exhibited increased transmigration through “matrigel”, which was specifically abrogated by the MMP inhibitor galardin or the plasmin inhibitor aprotinin. In VSMCs, E-LDL induced MMP-1 and MMP-2 secretion. Moreover, monocyte incubation with supernatants of E-LDL-treated (but not n-LDL-treated)VSMCs strongly induced MMP-9 in monoytes, which was inhibited by blocking mAb anti-TNF-α. Together, enzymatical modification of LDL allows a direct activation of MMP expression in monocytes and VSMCs, and indirectly promotes the induction of paracrine, cytokine-mediated intercellular activation processes. Thereby, E-LDL may contribute to atheroprogression, inflammation and plaque rupture.

Keywords

LDL - atherosclerosis - monocytes - smooth muscle cells - MMP

• References

• 1 Berliner JA, Navab M, Fogelman AM. et al. Atherosclerosis: Basic mechanisms. Circulation 1995; 91: 2488-96.
• 2 Libby P, Geng YJ, Sukhova GK. et al. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci 1997; 811: 134-42.
• 3 Falkenberg M, Tom C, De Young MB. et al. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci U S A 2002; 99: 10665-70.
• 4 Preissner KT, Kanse SM, May AE. Urokinase receptor: A molecular organizer in cell communication. Curr Opin Cell Biol 2000; 12: 621-8.
• 5 Rajavashisth TB, Xu XP, Jovinge S. et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators. Circulation 1999; 99: 3103-9.
• 6 Brown DL, Hibbs MS, Kearney M. et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-31.
• 7 Kataoka H, DeCastro R, Zucker S. et al. Tumor cellderived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 1993; 53: 3154-8.
• 8 Major TC, Liang L, Lu X. et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002; 22: 1200-7.
• 9 Sukhova GK, Schonbeck U, Rabkin E. et al. Evidence for increased collagenolysis by interstitial collagenases- 1 and –3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-9.
• 10 Bhakdi S, Dorweiler B, Kirchmann R. et al. On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182: 1959-71.
• 11 Steinbrecher UP, Parthasarathy S, Leake DS. et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 1984; 81: 3883-7.
• 12 Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
• 13 Parthasarathy S, Quinn MT, Schwenke DC. et al. Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. Arteriosclerosis 1989; 9: 398-404.
• 14 Cushing SD, Berliner JA, Valente AJ. et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990; 87: 5134-8.
• 15 Li D, Liu L, Chen H. et al. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003; 107: 612-7.
• 16 Torzewski M, Klouche M, Hock J. et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369-78.
• 17 Bhakdi S, Torzewski M, Klouche M. et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
• 18 Seifert PS, Hugo F, Tranum-Jensen J. et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 17: 547-57.
• 19 Bhakdi S, Torzewski M, Paprotka K. et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109: 1870-6.
• 20 Klouche M, Gottschling S, Gerl V. et al. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1376-85.
• 21 Han SR, Momeni A, Strach K. et al. Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 661-7.
• 22 Klouche M, May AE, Hemmes M. et al. Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers. Arterioscler Thromb Vasc Biol 1999; 19: 784-9.
• 23 Klouche M, Rose-John S, Schmiedt W. et al. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000; 101: 1799-805.
• 24 Klouche M, Peri G, Knabbe C. et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004; 175: 221-8.
• 25 Ziegler-Heitbrock HW, Thiel E, Futterer A. et al. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 41: 456-61.
• 26 May AE, Schmidt R, Kanse SM. et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002; 100: 3611-7.
• 27 May AE, Kälsch T, Massberg S. et al. Engagement of GPIIb/IIIa on platelets upregulates CD40L and triggers CD40L dependent matrix degradation by endothelial cells. Circulation 2002; 106: 2111-7.
• 28 Ardans JA, Economou AP, Martinson Jr JM. et al. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and –9 by activated monocytes. J Leukoc Biol 2002; 71: 1012-8.
• 29 Xu XP, Meisel SR, Ong JM. et al. Oxidized lowdensity lipoprotein regulates matrix metalloproteinase- 9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-8.
• 30 Bhakdi S, Lackner KJ, Han SR. et al. Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb Haemost 2004; 91: 639-45.
• 31 May AE, Neumann F-J, Preissner KT. The relevance of blood cell-vessel wall interactions for vascular thrombotic disease. Thromb Haemost 1999; 82: 962-9.
• 32 Torzewski M, Suriyaphol P, Paprotka K. et al. Enzymatic modification of low-density lipoprotein in the arterial wall. A new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 2130-6.